脉冲吸入一氧化氮治疗肺纤维化相关肺动脉高压风险的随机双盲安慰剂对照研究
本研究为2b/3期试验第一队列,纳入肺纤维化相关肺动脉高压(fILD-PH)患者,随机接受脉冲吸入一氧化氮30 μg/kg理想体重/h(iNO30)或安慰剂治疗8周。结果显示iNO30组中重度体力活动(MVPA)平均改善,安慰剂组MVPA平均下降26%、总体活动下降12%;开放标签扩展期各剂量iNO安全耐受。
要点
- iNO30治疗8周可改善fILD-PH患者MVPA,安慰剂组MVPA下降26%。
- iNO30组氧饱和度改善,开放标签扩展期活动参数维持稳定。
- iNO 30、45、75 μg/kg理想体重/h剂量均安全且耐受良好。
核心结论
- iNO30在MVPA上显示出临床和统计学显著获益,在总体活动上显示临床显著获益。
- 开放标签扩展期中更高剂量iNO安全耐受,活动参数维持稳定。
研究设计与样本
- 2b/3期试验第一队列,随机、双盲、安慰剂对照设计。
- 开放标签扩展期依次使用iNO30、iNO45、iNO75剂量。
主要发现
- 盲法治疗期间,iNO30组MVPA平均改善,总体活动保持稳定。
- 安慰剂组MVPA平均下降26%,总体活动平均下降12%。
- iNO组氧饱和度改善。
- 开放标签扩展期所有活动参数维持稳定,包括从下降转为维持的安慰剂组。
- iNO 30、45、75剂量均安全且耐受良好。
临床怎么用
- 对于fILD-PH患者,脉冲吸入一氧化氮30 μg/kg理想体重/h可能改善体力活动和氧饱和度。
- 治疗期间需监测活动能力和氧饱和度变化,并评估安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The interstitial lung diseases include a variety of disorders, many of which are characterized by fibrotic changes (fILD). Of the fILDs, Idiopathic pulmonary fibrosis is the most common. Pulmonary hypertension (PH) frequently complicates fILD and is associated with impaired functional capability, lower physical activity, and significantly reduced life expectancy. There is no proven treatment for patients with fILD-PH. We report results from the first cohort of a phase 2b/3 trial with pulsed inhaled nitric oxide (iNO) in patients with fILD-PH. METHODS: Subjects in cohort 1 were randomized to iNO 30 μg/kg ideal body weight/h (iNO30) or placebo for 8 weeks of blinded treatment; subjects then transitioned to open-label extension (OLE) on iNO30 followed by dose escalation to iNO45 then iNO75. Activity monitoring was used to assess changes in daily activity. Safety and efficacy were evaluated. RESULTS: Twenty-three patients were randomized to iNO30 and 18 to placebo. During blinded treatment, iNO30 subjects showed an average improvement in moderate/vigorous physical activity (MVPA) and remained stable in overall activity. Placebo subjects showed an average drop of 26% in MVPA and a 12% drop in overall activity. The iNO group had an improvement in oxygen saturation. During OLE, subjects maintained their activity levels including placebo subjects who transitioned from a decline to a maintenance in all activity parameters. Inhaled nitric oxide at all doses (30, 45, and 75) was safe and well tolerated. CONCLUSIONS: Treatment with iNO30 demonstrated clinically and statistically significant benefit in MVPA and clinically significant benefit in overall activity. In the OLE, higher doses of iNO were also safe and well tolerated while showing maintenance in activity parameters.
引用
- Nathan SD, Flaherty KR, Glassberg MK, et al. A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis. Chest. 2020. PMID: 32092321. doi:10.1016/j.chest.2020.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。